Estrogen Regulation of Cell Cycle Progression

  • Owen W. J. Prall
  • Eileen M. Rogan
  • Elizabeth A. Musgrove
  • Colin K. W. Watts
  • Robert L. Sutherland
Conference paper

Abstract

Estrogens (Es) are essential for the normal development and physiological function of the female reproductive tract and secondary sex organs including the mammary gland. The development and progression of cancer in adult E target tissues is also dependent on E which has led to the effective use of E antagonists, particularly tamoxifen, in the treatment and potential prevention of breast cancer. The involvement of E in these major physiological and pathological processes is thought to be mediated via the potent mitogenic activity of Es. While these properties of Es have been long appreciated, it is only recently that the links between E action and the cell cycle machinery have begun to be dissected.

Keywords

Filtration Estrogen Tamoxifen Estradiol Threonine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Prall OWJ, Sarcevic B, Musgrove EA et al. (1997) Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E/Cdk2. J Biol Chem 272:10882–10894.PubMedCrossRefGoogle Scholar
  2. 2.
    Sutherland RL, Hall RE and Taylor IW (1983) Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 43:3998–4006.PubMedGoogle Scholar
  3. 3.
    Taylor IW, Hodson PJ, Green MD et al. (1983) Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res 43:4007–4010.PubMedGoogle Scholar
  4. 4.
    Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323–330.PubMedCrossRefGoogle Scholar
  5. 5.
    Morgan DO (1995) Principles of Cdk regulation. Nature 374:131–134.PubMedCrossRefGoogle Scholar
  6. 6.
    Planas-Silva MD and Weinberg RA (1997) Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059–4069.PubMedGoogle Scholar
  7. 7.
    Watson PH, Pon RT and Shiu RP (1991) Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51:3996–4000.PubMedGoogle Scholar
  8. 8.
    Steiner P, Philipp A, Lukas J et al. (1995) Identification of a myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO Journal 14:4814–4826.PubMedGoogle Scholar
  9. 9.
    Prall OWJ, Rogan EM, Musgrove EA et al. (1998) c-myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18:4499–4508.PubMedGoogle Scholar
  10. 10.
    Perez-Roger I, Solomon DL, Sewing A et al. (1997) Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip 1) binding to newly formed complexes. Oncogene 14:2373–2381.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2001

Authors and Affiliations

  • Owen W. J. Prall
  • Eileen M. Rogan
  • Elizabeth A. Musgrove
  • Colin K. W. Watts
  • Robert L. Sutherland

There are no affiliations available

Personalised recommendations